News

Filter

Current filters:

3SBio

3SBio gains exclusive license for PharmAbcine’s tanibirumab

20-11-2014

Chinese biotech firm 3SBio Inc has entered into an exclusive license with PharmAbcine for the development,…

3SBioBiotechnologyBrazilChinaLicensingOncologyPharmAbcineRussiatanibirumabThailand

3SBio enters patent license agreement with DiNonA for Leukotuximab

3SBio enters patent license agreement with DiNonA for Leukotuximab

08-08-2014

Chinese biotechnology company 3SBio has entered into an exclusive license with Korean DiNonA for the…

3SBioBiotechnologyChinaDiNonAKoreaLeukemiaLeukotuximabLymphocytic leukemiaManufacturingMarkets & MarketingOncology

3SBio licenses pegsiticase to Selecta Biosciences to develop the gout drug candidate

3SBio licenses pegsiticase to Selecta Biosciences to develop the gout drug candidate

18-06-2014

China-based biotech firm 3SBio has entered into an exclusive license with Selecta Biosciences for pegsiticase…

3SBioAnti-Arthritics/RheumaticsBiotechnologyLicensingpegsiticaseSelecta Biosciences

3SBio acquires global rights to gout drug pegsiticase from EnzymeRx for just over $6 million

30-11-2010

Chinese biotechnology firm 3SBio (Nasdaq: SSRX) says that is has acquired worldwide rights of pegsiticase…

3SBioAnti-Arthritics/RheumaticsEnzymeRxLicensingpegsiticasePharmaceutical

Isotechnika sells China rights to transplant drug voclosporin to 3SBio in China for $6 million

25-08-2010

Chinese biotechnology firm 3SBio (Nasdaq: SSRX) and Canada’s Isotechnika Pharma (TSX: ISA) have…

3SBioBiotechnologyFinancialImmunologicalsIsotechnikaLicensingPharmaceuticalvoclosporin

Back to top